In-vivo studies on Transitmycin, a potent Mycobacterium tuberculosis inhibitor.

In-vivo studies on Transitmycin, a potent Mycobacterium tuberculosis inhibitor.

This study involves the in-vitro and in-vivo anti-TB potency and in-vivo safety of Transitmycin (TR) (PubChem CID:90659753)- identified to be a novel secondary metabolite derived from Streptomyces sp (R2). TR was tested in-vitro against drug resistant TB clinical isolates (n = 49). 94% of DR-TB stra...

Full description

Bibliographic Details
Main Authors: Rajesh Mondal, Azger Dusthackeer V N, Palaniyandi Kannan, Amit Kumar Singh, Kannan Thiruvengadam, Radhakrishnan Manikkam, Shainaba A S, Mahizhaveni Balasubramanian, Padmasini Elango, Sam Ebenezer Rajadas, Dinesh Bharadwaj, Gandarvakottai Senthilkumar Arumugam, Suresh Ganesan, Hemanth Kumar A K, Manjula Singh, Shripad Patil, Jaleel U C A, Mukesh Doble, Balagurunathan R, Srikanth Prasad Tripathy, Vanaja Kumar
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2023-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0282454

Internet

https://doi.org/10.1371/journal.pone.0282454

Similar Items